Issue link: https://viewer.e-digitaledition.com/i/962601
symptoms worse. A few studies before ours didn't see worsening. Ever yone criticizes the duration of [those] studies, so we undertook this one to [fi nd out] if we were to go back and evaluate patients who've been on this treatment seven, eight, 10 years, what would we see?" ENCOURAGING RESULTS The study examined 656 men, most in their 50s and 60s, who received treatment for hypogonadism at a urolog y clinic in Germany. A group of 360 men received i nje c t a ble t e s t o s t er one u nde c a no - ate ever y 12 weeks for up to 10 yea rs; the in-off ice nature of the treatment ensured 100 percent patient compliance. The 296 men who chose not to receive testosterone served as a control group. The researchers identifi ed 82 men from each group for comparative examination. The median follow-up period for both groups was eight years. M e n w h o r e c e i v e d t e s t o s t e r on e therapy ex perienced fewer LUTS, a s well a s improvement in erectile dys- f unction a nd increa ses in qua lit y of life. Measurements of post-void blad- der volume found that the men in the testosterone group were able to empty their bladders more successfully. Men in the non-testosterone group saw LUTS rise, erectile function fa ll and qua lity of life decrease. They a lso experienced increa sing dif f icu lt y w ith empt y ing the bladder. "The literature is replete with argu- ment s t h a t t e s t o s t er one i ncr e a s e s prostate volume and, therefore, wors- ens LUTS," Traish says. "However, our study and severa l others have demon- strated that testosterone therapy does not worsen LUTS; on the contra r y, it improves them." One of Traish's coauthors, urologist A hmad Haider, Dr. Med., whose clinic in Germany compiled the registry used in the study, says the leng thy follow-up "revealed some hitherto unknown eff ects of testosterone therapy." " I li ke to t hin k t hat we see a slow reversa l of a situation that has gotten out of balance," he says. Dr. Ha ider g ives t he exa mple of a man who has become obese over many yea rs a s t he resu lt of poor d iet a nd inactivity. Obesity is associated with low testosterone. "The man gets his testosterone nor- ma lized, he sta r ts feeling better, his muscle mass comes back slowly, he gets more active ... and things start to slowly improve," Dr. Haider says. "The fact that we still see improvements after 10 years of treatment speaks to this hypothesis." REASONS FOR CAUTION Glenn R. Cunningham, MD, Distinguished P r o f e s s o r E m e r i t u s o f M e d i c i n e (Endocrinolog y) at Baylor College of Medicine, who was not involved in the study, points to its non-randomized nature and lower threshold for diagnosing hypo- gonadism than those of recent clinical trials as reasons for skepticism. "The testosterone group had a baseline BMI of 33.1, and the control group had a BMI of 29.3," Dr. Cunningham says. "Total testosterone levels a re decrea sed in obese men [ but free testosterone levels may remain in the norma l range], so it is likely that ma ny of these men were not hypogonada l." Recent fi ndings will likely continue t o g ive phy s ic i a n s pa u s e . I n 2 017, researchers revea led the results of the one-year, NIH-supported Testosterone Tria ls, which examined the use of tes- tosterone in nea rly 800 hy pogonada l men age 65 a nd older. The treatment i ncrea sed volu met r ic bone m i nera l density a nd bone streng th, as well as hemoglobin levels in men with anemia, compared with controls. However, men in the testosterone group were found to have more nonca lcif ied plaque in their corona r y a r teries — a risk fac- tor for heart attack — at the end of the study. Other studies have shown that testosterone therapy ha s no adverse eff ects on the hea r t, a nd may even be protective, according to Traish. Longer, larger studies are needed to corroborate the Testosterone Tria ls' fi ndings. "There's reasonable evidence out there to give a three- or six-month [testoster- one therapy] trial," Traish says, "and if the patient doesn't benefi t, take him off the therapy." n Weight Loss and Male Hypogonadism Hypogonadal men who received injectable testosterone therapy as part of a recent study at a German urology clinic gradually lost weight throughout a follow-up period of up to 10 years, in contrast with patients who have received transder- mal treatment. "[O]ur study is different as a result of the 100 percent adherence [to treatment] and the lack of absorption problems [that] may occur with transdermal treat- ment, especially in obese men," says Ahmad Haider, Dr. Med., a urologist at the clinic where the men received treatment and an author of the study. "The weight loss and the improved body composition may play a crucial role in many of the other improvements [witnessed in the study]. It is well-known that obesity is a risk factor for lower urinary tract symptoms as well as for erectile dysfunction and even prostate cancer." SPECIAL CLINICAL SECTION: MEN'S HEALTH M D N E W S . C O M /// M D N E W S L O W E R H u D S O N / B R O N x ■ 2 018 1 5

